Biogen Details $5.6B Apellis Deal, Sees Mid-to-High-Teens Growth and EPS Accretion by 2027

Adam Keeney , Head of Corporate Development, said the acquisition would add “two best-in-class products” to Biogen’s growth portfolio: Syfovre in geographic atrophy (GA) and Empaveli across rare hematology and kidney diseases.Viehbacher laid out several criteria he said would need to be met for an acquisition, including staying aligned with Biogen’s broadened focus beyond neuroscience into “neurology, immunology, and rare diseases,” avoiding excessive balance sheet stretch, keeping the deal size around “$5 ...